Clinical trial · Observational
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT04436679CI-TRIAL-00087882CaPaLongcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.
- timeFrame
- at 2 years
- description
- Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.
Secondary outcomes (1)
- measure
- Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.
- timeFrame
- at 2 years
- description
- Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years of age at diagnosis * Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016 * Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma * Tissue blocks (FFPE) available (tumour/healthy tissue) * Affiliated to a social security scheme Exclusion Criteria: * Absence of Primary Cancer Tissue Blocks (PCTBs) * Paraffin block fixed in Bouin or AFA * Patient Refusal * Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...). * Patient died due to post-surgical complications (death within 30 days post-surgery). * Surgical resection of macroscopic R2 type.
References
Publications (0)
Data not yet available
No reference posted for this study.